Table 3.

Eligibility of CTT participants without a history of vascular disease for statin therapy under existing major guidelines, by estimated 5-year major vascular event risk

		Observed MCE event rate (% per annum)*	Observed vascular death rate (% per annum)*	Broad eligibility under current guidelines
				ATP-III†	ESC task force‡	NICE§
CTT risk category
	<5%	0·2	0·1	×	×	×
	≥5% to <10%	0·8	0·3	×	×	×
	≥10% to <20%	1·6	1·0	P	P	P
	≥20% to <30%	3·2	2·3	P	P	P
	≥30%	5·6	5·8	P	P	P

CTT=Cholesterol Treatment Trialists'. MCE=major coronary event.

^*Among control-allocated participants without a history of vascular disease.

^†The Adult Treatment Panel III (ATP III) of the National Cholesterol Education p rogram in the USA.

^‡The Fourth Joint Task Force of the European Society of Cardiology (ESC) and Other Societies on Cardiovascular Disease Prevention in Clinical Practice and the ESC/EAS Guidelines for the management of dyslipidaemias.

^§The National Institute for Health and Clinical Excellence (NICE) in the National Health Service in England and Wales.